Rhumbline Advisers Boosts Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Rhumbline Advisers raised its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 5.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 310,539 shares of the biotechnology company’s stock after purchasing an additional 15,844 shares during the period. Rhumbline Advisers owned about 0.13% of ADMA Biologics worth $3,472,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Viewpoint Capital Management LLC raised its holdings in ADMA Biologics by 18.6% in the first quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 2,416 shares in the last quarter. Eagle Asset Management Inc. raised its stake in shares of ADMA Biologics by 20.2% in the 4th quarter. Eagle Asset Management Inc. now owns 25,957 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 4,367 shares in the last quarter. CWM LLC lifted its position in shares of ADMA Biologics by 114.2% during the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after purchasing an additional 4,367 shares during the last quarter. ProShare Advisors LLC lifted its position in shares of ADMA Biologics by 9.2% during the first quarter. ProShare Advisors LLC now owns 54,293 shares of the biotechnology company’s stock worth $358,000 after purchasing an additional 4,570 shares during the last quarter. Finally, EntryPoint Capital LLC acquired a new position in ADMA Biologics in the first quarter worth about $31,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at ADMA Biologics

In related news, Director Lawrence P. Guiheen sold 9,000 shares of ADMA Biologics stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the sale, the director now directly owns 153,941 shares in the company, valued at approximately $2,843,290.27. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, Director Lawrence P. Guiheen sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the sale, the director now directly owns 153,941 shares in the company, valued at approximately $2,843,290.27. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Adam S. Grossman sold 236,889 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the transaction, the chief executive officer now owns 2,059,726 shares of the company’s stock, valued at approximately $36,436,552.94. The disclosure for this sale can be found here. Over the last quarter, insiders sold 466,900 shares of company stock worth $8,224,121. Insiders own 3.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ADMA. HC Wainwright upped their price objective on ADMA Biologics from $10.00 to $18.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Cantor Fitzgerald raised their price objective on ADMA Biologics from $15.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. Finally, Mizuho lifted their price objective on shares of ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, June 20th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $15.50.

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $18.71 on Wednesday. The company has a market cap of $4.34 billion, a P/E ratio of -935.50 and a beta of 0.61. The business has a 50 day moving average of $15.33 and a two-hundred day moving average of $10.71. ADMA Biologics, Inc. has a 52 week low of $3.06 and a 52 week high of $19.34. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The business had revenue of $107.20 million during the quarter, compared to analyst estimates of $86.44 million. During the same quarter in the previous year, the firm posted ($0.02) EPS. The business’s revenue for the quarter was up 78.4% compared to the same quarter last year. As a group, analysts anticipate that ADMA Biologics, Inc. will post 0.49 EPS for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.